Investor FAQ

Show all
Strongbridge Biopharma is an Irish public limited company.
The U.S. operations are based in Trevose, Pennsylvania, USA.
Strongbridge Biopharma was established in 1996.
Strongbridge Biopharma priced its initial public offering on NASDAQ Global Market on October 16, 2015 and trades under the ticker symbol SBBP.
Strongbridge Biopharma’s CUSIP number is G85347 105.
Communication regarding transfer requirements, lost certificates, changes of address, etc., should be directed to: Computershare

Written Inquiries:

PO Box 43001
Providence RI 02940-30001

Or by overnight delivery:
250 Royall St.
Canton, MA 02021

Email Inquiries:
[email protected]

Telephone Inquiries:
Toll-Free: 866-490-6058 (US, Canada, Puerto Rico)
781-575-2784 (non-US)

Online Inquiries:
Strongbridge Biopharma’s fiscal year end is December 31.
You may sign up to receive Strongbridge Biopharma’s press releases and SEC filings at the following link: Email Alerts.
Strongbridge Biopharma’s U.S. Securities and Exchange Commission filings can be viewed on the SEC page.
For investor relations inquiries, you may submit inquiries via [email protected], or by contacting Marcy Nanus at The Trout Group, LLC. at +1-646-378-2927 or [email protected].

For corporate or media relations inquiries, you may submit inquiries via [email protected], or by contacting Lindsay Rocco at Elixir Health Public Relations at +1-862-596-1304 or [email protected].

© 2021 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA® is a registered trademark of the Strongbridge Biopharma plc. companies, which include Strongbridge Dublin Limited and Strongbridge U.S. Inc.
KEVEYIS® is a registered trademark licensed exclusively in the U.S. to Strongbridge Biopharma plc.
MLR-0010 V16 03/2020

  • Ireland Address:
    Suite 206, Fitzwilliam Hall
    Fitzwilliam Place, Dublin 2, D02 T292
  • U.S. Address:
    900 Northbrook Drive, Suite 200
    Trevose, PA 19053
    United States

Phone: +1 610-254-9200
[email protected]

Privacy Statement
Compliance Program